Mademont Sole, IreneMates, JesúsFernández Ávila, Ana IsabelYotti, RaquelEspinosa, Mª ÁngelesPérez Serra, AlexandraColl, MónicaMéndez, IreneIglesias, AnnaDel Olmo, BernatRiuró, HelenaCuenca, SofíaAllegue, CatarinaCampuzano, ÓscarPicó, FerránFerrer Costa, CarlesÁlvarez, PatriciaCastillo, SergioGarcía Pavía, PabloGonzález López, EstherPadrón Barthe, LauraDíaz de Bustamante, AránzazuDarnaude, María TeresaGonzález Hevia, José IgnacioBrugada, JosepFernández Avilés, FranciscoBrugada, Ramón2018-02-052018-02-0520171932-6203http://hdl.handle.net/10641/1385Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited heart disease. Three hundred and eighty-seven consecutive unrelated patients with HCM were screened for genetic variants in the 5 most frequent genes (MYBPC3, MYH7, TNNT2, TNNI3 and TPM1) using Sanger sequencing (N = 84) or NGS (N = 303). In the NGS cohort we analyzed 20 additional minor or candidate genes, and applied a proprietary bioinformatics algorithm for detecting CNVs. Additionally, the rate and classification of TTN variants in HCM were compared with 427 patients without structural heart disease. A small percentage of HCM cases without point mutations in the 5 main genes are explained by P/LP variants in minor or candidate genes and CNVs. Screening for variants in TTN in HCM patients drastically increases the number of inconclusive tests, and shows a rate of VUS that is similar to patients without structural heart disease, suggesting that this gene should not be analyzed for clinical purposes in HCM. Nextgeneration sequencing (NGS) is the preferred genetic test, but the diagnostic value of screening for minor and candidate genes, and the role of copy number variants (CNVs) deserves further evaluationengAtribución-NoComercial-SinDerivadas 3.0 Españahttp://creativecommons.org/licenses/by-nc-nd/3.0/es/Hypertrophic cardiomyopathyjournal articleopen access